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lesion characteristics, glycoprotein IIb/IIIa inhibitor use, and TFG
3 (odds ratio [OR] for TMPG 2/3 of 1.7, 95% confidence interval
[CI] 1.3 to 2.3, n  1,068, p  0.001). This association persisted
despite the inclusion of the propensity score for smoking, as well as
in a model incorporating WBCC, hemoglobin, platelet count, and
CRP (OR 2.0, CI 1.3 to 3.1, n  461, p  0.001). Finally, when
the propensity score was used to generate matched cohorts of
smokers and nonsmokers, the magnitude of the association be-
tween smoking and higher TMPG was similar to that in the
overall unmatched population.
This analysis demonstrates that smokers with STEMI have im-
proved myocardial perfusion after fibrinolytic therapy, as compared
with nonsmokers, despite adjustment for differences in age, comor-
bidities, previous medications, and other potential confounders, and
additionally in analyses stratified by TFG and TRS. This finding
lends support to the hypothesis that smokers have more complete clot
lysis after fibrinolytic administration, which results in improved
myocardial perfusion independent of epicardial artery flow. Smoking
has been associated with better clinical outcomes after fibrinolytic
administration in STEMI patients, but the underlying mechanism
responsible for the so-called “smoker’s paradox” remains unclear.
Several angiographic analyses have demonstrated faster epicardial flow
among smokers, independent of baseline covariates (3). Although we
observed no significant differences in 60-min epicardial flow, this may
be due to the angiographic time point used, because among patients
who had available 90-min data, the incidence of TFG 3 was
significantly higher among smokers at 90 min (data not shown).
Smoking may not increase plaque vulnerability as much as it
intensifies hypercoagulability. It is notable that the association
between smoking and improved myocardial perfusion was inde-
pendent of the higher WBCC and CRP levels in smokers. As
elevated inflammatory markers are associated with impaired myo-
cardial perfusion, this may reflect differing roles of inflammatory
markers between smokers and nonsmokers. Smoking has been
associated with higher levels of procoagulant factors (1), and
soluble components of cigarette smoke have also been shown to
impair fibrin cross-linking (6). These findings support the hypoth-
esis that the pathogenesis of STEMI in smokers may be less
atherogenic but more thrombogenic and therefore more responsive
to fibrinolytic therapy.
It could be speculated that our findings may reflect more
complete fibrinolysis with reduced distal embolization and micro-
vascular dysfunction among smokers. Although our study was not
powered to detect differences in clinical outcomes, insofar as
improvements in myocardial perfusion have been associated with
better outcomes in STEMI, the association between smoking and
better myocardial perfusion may explain, at least in part, the
improved prognosis of smokers in this clinical setting.
Spontaneous fibrinolysis and/or epicardial coronary vasospasm
may have occurred more frequently among smokers, which may be
a mechanism of a seemingly superior response to fibrinolytic
therapy. Despite efforts to adjust for baseline characteristics and
covariates, including the reperfusion regimen, this analysis is a
nonrandomized, retrospective analysis of pooled clinical trials, and
as such, it is possible that both identified and unidentified residual
confounders may have influenced the outcomes.
Smoking is independently associated with improved myocardial
perfusion after fibrinolytic therapy, despite adjustment for multiple
baseline clinical characteristics. This finding may partly explain the
improved outcomes of smokers with STEMI treated with fibrino-
lytic therapy.
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Letters to the Editor
Coronary Stenting Versus
Balloon Angioplasty in Small Vessels
We read with interest the study by Moreno et al. (1), which
demonstrated, through a meta-analytic technique, the significant
reduction of restenosis due to stent in comparison to percutaneous
transluminal coronary angioplasty in small-vessel coronary artery
disease. However, the investigators failed to emphasize that
substantial statistical heterogeneity was present, as shown in their
overall analysis in Figure 1 (p for heterogeneity  0.019).
We believe that this constitutes a methodological flaw in the
study. Indeed, substantial heterogeneity is considered by several
investigators to be a contraindication to quantitative pooling
323JACC Vol. 45, No. 2, 2005 Correspondence
January 18, 2005:318–28
analysis (2), although other authorities recommend the need for
summary measures for the best estimate of the impact of an
intervention, albeit that correct methodological techniques are
used to investigate the differences among single trials (3).
Furthermore, Moreno et al. (1) tried to assess, by means of
linear regression analysis, the possible association of several angio-
graphic variables with the benefit of stents, finding a significant
inverse relationship between reference vessel diameter (RVD) and
the risk reduction of angiographic restenosis after stent placement
with respect to balloon angioplasty (i.e., the smaller the vessel, the
larger the benefit of stenting). However, we believe the correct
methodological tool to address whether a covariable may have a
significant effect on the outcome in a meta-analysis is meta-
regression (4). Using this technique (which weights each study
according to its statistical weight [i.e., the inverse of the variance])
to analyze the very same data presented in their study, we did not
find any significant relation between RVD and risk reduction of
angiographic restenosis after stent placement.
Moreover, another recent trial, published only as an abstract (5),
did not confirm the investigators’ hypothesis. Indeed, in front of
the smallest mean RVD of all the trials on small-vessel disease
(2.17 mm), there was a nonsignificantly increased risk of restenosis
(relative risk 1.14 [95% confidence interval 0.89 to 1.48]) after
stenting.
Finally, meta-analytic techniques allow quantitative assessment
of treatment effects from pooled data. With the widening of their
use and because of potential errors, improper analyses may result in
misleading conclusions; thus, optimal methodological procedures
should be utilized to validate findings.
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REPLY
We acknowledge Dr. Agostoni and colleagues for their interest in
our work, but we do not agree with their comments. Heterogeneity
between studies is not a contraindication to quantitative pooling
analysis. When analyzing the effect of a therapeutic mean, two
different types of analysis can be performed: random-effect model
(between-trial variance and within-trial variance) and fixed-effect
model (1,2). The first type is used when significant heterogeneity
exists, whereas the fixed-effect model assumes that between-trial
variance is zero. As we clearly specified in our Methods, we used
the random-effect model (3). As Agostoni and colleagues empha-
size, controversy abounds concerning the best approach when
heterogeneity exists, but we believe the investigators consider this
methodology correct. In fact, in a very recently published meta-
analysis, they concluded that radial access yields to lower proce-
dural success than does femoral access, despite having found
significant heterogeneity between studies when evaluating this end
point (4).
Also, it is important to consider the causes of heterogeneity
among trials. In our study, heterogeneity was not due to clinical or
design discrepancies between the studies, but rather to differences
in the number of patients included (treatment favored balloon only
in the COMPASS trial (5) and in the study by Park et al. (6), and
these had the lowest number of patients).
The second criticism raised by Agostoni and colleagues is that
the relationship between risk ratio for restenosis and reference
vessel diameter (RVD) should have been adjusted by the inverse of
variance. Apparently they were unable to find (data not provided)
any significant relation between both variables. Accordingly, we
have analyzed our data after adjusting this relation for the inverse
of variance (7–9). After analyzing it, the association between RVD
and risk reduction remained significant, and in fact the beta-
coefficient for RVD was even higher (Y6.514 2.674 [RVD]
 2.156 [varRR]); p value for RVD  0.017).
Moreover, ever since we wrote up the study, several randomized
trials comparing stent and balloon in small vessels have been
reported and even published (10–12). Dr. Agostoni and colleagues
only mention the recently reported ISAR SMART-2 trial, in
which coronary stenting was nonsuperior to balloon in small
coronary vessels. The ISAR–SMART-2, however, has one impor-
tant limitation not recognized by Agostoni et al: the very high rate
of cross-over from balloon to stent (40%, in comparison with
19% in our meta-analysis) (10). Unfortunately, they do not
mention the already published study by Kinsara et al. (12), in
which restenosis rate decreased from 49% to 30% (balloon and
stent, respectively; p 0.009) in very small vessels (2.09 mm). The
same occurs with the LASMAL-II trial, in which angiographic
restenosis significantly decreased from 45% to 28%, respectively (p
 0.043) (11).
Interventional cardiology is one of the areas of medicine in
which most randomized trials are being performed. Because of
that, we may be tempted to use meta-analytic techniques without
profound knowledge of the trials included and the methodologies
employed. To avoid improper conclusions, it is necessary to
understand adequately the meta-analytic techniques and their
limitations, to obtain advice from expert statisticians, and to
evaluate thoroughly all the trials included. This methodology
allowed us to conclude that coronary stenting reduces the reste-
nosis rate in comparison to balloon angioplasty in small coronary
arteries (3).
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